COLOMBIA WOUND CARE BIOLOGICS MARKET ANALYSIS

Colombia Wound Care Biologics Market, by Product Type (Biologic Skin Substitutes, Enzyme Based Formulations, and Growth Factors), by Application (Chronic Wounds (Diabetic Foot Ulcer, Venous Leg Ulcer, and Pressure Ulcer) and Acute Wounds (Surgical Wounds and Burns)), by End User (Hospitals, Clinics, Ambulatory Surgical Centers, and Home Care Settings) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Published In : Aug 2023
Code : CMI4892
Pages :111
Formats :
Excel and PDF
Industry : Pharmaceutical

Market News

The increasing product launches are expected to drive the market growth over the forecast period.

For instance, in September 2020, MiMedx Group, Inc. an industry leader in advanced wound care and an emerging therapeutic biologics company, launched EpiCord Expandable. EpiCord Expandable is clinically efficient to use for the treatment of diabetic foot ulcers.

The increasing mergers and acquisitions by the key players is expected to drive the market growth over the forecast period.

For instance, in June 2018, Acelity L.P. Inc., the world’s largest wound care company and Crawford Healthcare U.K.-based advanced wound care and dermatology company entered into an acquisition agreement. Under which Acelity would acquire Crawford with all of its assets. Therefore, this acquisition would expand Acelity’s portfolio of advanced wound dressings.

The increasing product approvals are expected to drive the market growth over the forecast period.

For instance, in July 2018, ConvaTec Group Plc, a leading global medical products and technologies company, received the U.S. Food and Drug Administration (FDA) approval for its innovative and advanced antimicrobial dressing AQUACEL Ag Advantage dressing for wound management.